STAFFORD, Texas--(BUSINESS WIRE)-- Microvast Holdings, Inc. (NASDAQ: MVST), a technology innovator that designs, develops and manufactures lithium-ion battery solutions, today announced the fifth ...
Bristol Myers Squibb (BMS) has agreed to acquire Mirati Therapeutics for up to $5.8 billion, the companies said, in a deal that expands the buyer’s cancer portfolio with Mirati’s marketed drug Krazati ...
The drugmaker's best-selling products in the period were anticoagulant Eliquis and cancer medicine Opdivo; BMS shares the rights to the former medicine with Pfizer. Eliquis' revenue increased by 7% ...
BMS aims to strengthen its pipeline of cancer treatments and will add Mirati’s lung cancer medicine to its commercial portfolio. Global biopharma company Bristol Myers Squibb (BMS) has entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results